Bile-induced secretion of glucagon-like peptide-1: Pathophysiological implications in type 2 diabetes?

American Journal of Physiology - Endocrinology and Metabolism

Volumn 299, Issue 1, 2010, Pages

  Knop, Filip K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; THYROTROPIN;

BILE; CALCIUM TRANSPORT; CELL NUCLEUS; FOOD INTAKE; GALLBLADDER; GASTROINTESTINAL MOTILITY; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HYPOTHALAMUS; IN VIVO STUDY; INSULIN RELEASE; LAMINA PROPRIA; MICROVILLUS; MOUSE; NERVE FIBER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PARACRINE SIGNALING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SENSORY NERVE;

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OBESITY; POSTPRANDIAL PERIOD; RECEPTORS, G-PROTEIN-COUPLED;

EID: 77953403465     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00137.2010     Document Type: Review

References (52)

1. Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, Tierney RP, Modlin IM. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 34: 1219-1224, 1993.
2. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286: R269-R272, 2004.
3. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454, 2000.
4. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and metaanalysis. JAMA 292: 1724-1737, 2004. (Pubitemid 39346675)
5. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahren B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 295: E779-E784, 2008.
6. De Santis A, Attili AF, Ginanni CS, Scafato E, Cantagalli A, De LC, Pinto G, Lisi D, Capocaccia L. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 25: 787-790, 1997. (Pubitemid 27157115)
7. Dumoulin V, Dakka T, Plaisancie P, Chayvialle JA, Cuber JC. Regulation of glucagon-like peptide-1- (7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 136: 5182-5188, 1995.
8. Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M, Sasaki H. Response of truncated glucagon- like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetol 32: 165-169, 1995.
9. Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52: 1147-1154, 2003. (Pubitemid 36523349)
10. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1- (7-36)amide is transformed to glucagon-like peptide-1- (9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363, 1999.
11. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278: E1010-E1018, 2000.
12. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90-94, 2005. (Pubitemid 40215843)
13. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev 87: 1409-1439, 2007.
14. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48: 612-615, 2005. (Pubitemid 40591213)
15. Holst JJ, Rasmussen TN, Harling H, Schmidt P. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas 8: 80-87, 1993. (Pubitemid 23005581)
16. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
17. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386-390, 2005. (Pubitemid 40255465)
18. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56: 1951-1959, 2007.
19. Knop FK, Vilsbøll T, Holst JJ. Incretin-based therapy of type 2 diabetes mellitus. Curr Protein Pept Sci 10: 46-55, 2009.
20. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50: 797-805, 2007. (Pubitemid 46355821)
21. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 128: 97-107, 2005.
22. Le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243: 108-114, 2006. (Pubitemid 43054062)
23. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365, 1999. (Pubitemid 29289663)
24. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med 17: 713-719, 2000.
25. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane- type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298: 714-719, 2002. (Pubitemid 35356798)
26. Meier JJ, Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 4: 606-607, 2008.
27. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57: 1340-1348, 2008.
28. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43, 2004.
29. Namba M, Matsuyama T, Horie H, Nonaka K, Tarui S. Inhibition of pancreatic exocrine secretion and augmentation of the release of gut glucagon-like immunoreactive materials by intraileal administration of bile in the dog. Regul Pept 5: 257-262, 1983. (Pubitemid 13132562)
30. Namba M, Matsuyama T, Itoh H, Imai Y, Horie H, Tarui S. Inhibition of pentagastrin-stimulated gastric acid secretion by intraileal administration of bile and elevation of plasma concentrations of gut glucagon-like immunoreactivity in anesthetized dogs. Regul Pept 15: 121-128, 1986. (Pubitemid 16012197)
31. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423, 1991.
32. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368, 1999. (Pubitemid 29289664)
33. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17: 1671-1677, 2009.
34. Plaisancie P, Bernard C, Chayvialle JA, Cuber JC. Regulation of glucagon-like peptide-1- (7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology 135: 2398-2403, 1994.
35. Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1- secreting cells. Diabetes 51: 2757-2763, 2002.
36. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532-539, 2008.
37. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140: 1687-1694, 1999.
38. Shaw SJ, Hajnal F, Lebovitz Y, Ralls P, Bauer M, Valenzuela J, Zeidler A. Gallbladder dysfunction in diabetes mellitus. Dig Dis Sci 38: 490-496, 1993.
39. Stone BG, Gavaler JS, Belle SH, Shreiner DP, Peleman RR, Sarva RP, Yingvorapant N, Van Thiel DH. Impairment of gallbladder emptying in diabetes mellitus. Gastroenterology 95: 170-176, 1988.
40. Sugiyama K, Manaka H, Kato T, Yamatani K, Tominaga M, Sasaki H. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 55: 24-28, 1994.
41. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290: E550-E559, 2006.
42. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177, 2009.
43. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7: 678-693, 2008.
44. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717-3723, 2001. (Pubitemid 32755966)
45. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613, 2001. (Pubitemid 32195226)
46. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713, 2003. (Pubitemid 36724446)
47. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57: 678-687, 2008.
48. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543-553, 1999. (Pubitemid 29268438)
49. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489, 2006.
50. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7-36 amide and peptide YY from the L cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29: 501-505, 1994.
51. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 275: G984-G992, 1998.
52. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597-601, 1997. (Pubitemid 27278325)